,i #aahth ,,congress #ast ,session ,h4 ,r4 #cefa ,,in ,,the ,,house ,,of ,,representatives ,may #bb1 #bjbc ,mrs4 ,rodgers of ,washington 7for herself and ,mr4 ,pallone7 introduced the following bill2 which was referred to the ,committee on ,energy and ,commerce1 and in addition to the ,committees on ,ways and ,means1 and ,education and the ,workforce1 for a period to be subsequently determined by the ,speaker1 in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned ,a ,,bill ,to promote hospital and insurer price transparency1 and for other purposes4 #a4 ,short title ,this ,act may be cited as the ,promoting ,access to ,treatments and ,increasing ,extremely ,needed ,transparency ,act of #bjbc or the ,,patient ,act of #bjbc4 ,i ,increasing price transparency to lower costs #aja4 ,price transparency requirements 7a7 ,in general ,section #bgah7;e7 of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #cjj;gg-#ah7;e77 is amended-- 7#a7 by striking ,each hospital and inserting the following3 7#a7 ,in general ,each hospital 2 7#b7 by inserting 1 without subscription and free of charge1 in a single machine-readable file1 after a list2 7#c7 by inserting and a list1 in plain language and without subscription and free of charge1 in a consumer-friendly format1 of the hospital's standard charges for as many of the #gj ,centers for ,medicare ,medicaid ,services-specified shoppable services that are provided by the hospital1 and as many additional hospital-selected shoppable services 7or all such additional services1 if such hospital provides fewer than #cjj shoppable services7 as may be necessary for a combined total of at least #cjj shoppable services after ,social ,security ,act2 and 7#d7 by adding at the end the following3 ,such lists shall be updated not less frequently than annually4 ,beginning ,january #a1 #bjbd1 each hospital shall include in its lists of standard charges1 along with such additional information as the ,secretary may require with respect to such charges for purposes of promoting public awareness of hospital pricing in advance of receiving a hospital item or service1 the following3 7,a7 ,a plain language description of each item or service included on such list1 including1 as applicable1 the ,healthcare ,common ,procedure ,coding ,system 7,,hcpcs7 code1 the ,diagnosis ,related ,group 7,,drg71 the ,national ,drug ,code 7,,ndc71 or other payer identifier used or approved by the ,centers for ,medicare ,medicaid ,services for such item or service4 7,b7 ,the gross charge1 expressed as a dollar amount1 for each such item or service1 when provided in1 as applicable1 the hospital inpatient setting and outpatient department setting4 7,c7 ,any current payer-specific negotiated charges1 clearly associated with the name of the third party payer and plan and expressed as a dollar amount1 that applies to each such item or service when provided in1 as applicable1 the hospital inpatient setting and outpatient department setting4 7,d7 ,the de-identified maximum and minimum negotiated charges for each such item or service4 7,e7 ,the discounted cash price1 expressed as a dollar amount1 for each such item or service when provided in1 as applicable1 the hospital inpatient setting and outpatient department setting4 ,if the discounted cash price is a percentage of another value provided1 the calculated value must be entered as a dollar amount4 ,if the discounted cash price equates to the gross charge1 the gross charge shall be re-entered to indicate that no cash discount is available4 7#b7 ,deemed compliance with shoppable services requirement for certain years ,with respect to a year before #bjbe1 a hospital shall be deemed to meet the requirement of paragraph 7#a7 that such hospital make available a list of standard charges for shoppable services if the hospital maintains an internet-based price estimator tool that meets the following requirements3 7,a7 ,the tool provides estimates for as many of the #gj ,centers for ,medicare ,medicaid ,services specified shoppable services that are provided by the hospital1 and as many additional hospital-selected shoppable services 7or all such additional services1 if such hospital provides fewer than #cjj shoppable services7 as may be necessary for a combined total of at least #cjj shoppable services4 7,b7 ,the tool allows health care consumers to1 at the time they use the tool1 obtain an estimate of the amount they will be obligated to pay the hospital for the shoppable service4 7,c7 ,the tool is prominently displayed on the hospital's website and easily accessible to the public1 without subscription1 fee1 or having to submit personal identifying information1 and searchable by service description1 billing code1 and payer4 ,the ,secretary may not deem the establishment of an internet-based price estimator tool that meets the requirements of this paragraph to constitute compliance with the requirement of paragraph 7#a7 that such hospital make available a list of standard charges for shoppable services for #bjbe or a subsequent year4 7#c7 ,uniform method and format ,not later than ,january #a1 #bjbe1 the ,secretary shall implement a standard1 uniform method and format for hospitals to use in order to satisfy the requirements of this subsection for disclosing directly to the public charge and price information4 ,such method and format may be similar to any template established by the ,centers for ,medicare ,medicaid ,services as of the date of the enactment of this paragraph for reporting such information under this subsection and shall meet such standards as determined appropriate by the ,secretary4 7#d7 ,monitoring of pricing information ,the ,secretary1 in consultation with the ,inspector ,general of the ,department of ,health and ,human ,services1 shall1 through notice and comment rulemaking1 establish a process to regularly monitor the accuracy and validity of pricing information displayed by each hospital pursuant to paragraph 7#a74 7#e7 ,definitions ,notwithstanding any other provision of law1 for the purpose of paragraphs 7#a7 and 7#b73 7,a7 ,de-identified maximum negotiated charge ,the term de-identified maximum negotiated charge means the highest charge that a hospital has negotiated with all third party payers for an item or service4 7,b7 ,de-identified minimum negotiated charge ,the term de-identified minimum negotiated charge means the lowest charge that a hospital has negotiated with all third party payers for an item or service4 7,c7 ,discounted cash price ,the term discounted cash price means the charge that applies to an individual who pays cash1 or cash equivalent1 for a hospital item or service4 ,hospitals that do not offer self-pay discounts may display the hospital's undiscounted gross charges as found in the hospital chargemaster4 7,d7 ,gross charge ,the term gross charge means the charge for an individual item or service that is reflected on a hospital's chargemaster1 absent any discounts4 7,e7 ,payer-specific negotiated charge ,the term payer-specific negotiated charge means the charge that a hospital has negotiated with a third party payer for an item or service4 7,f7 ,shoppable service ,the term shoppable service means a service that can be scheduled by a health care consumer in advance4 7,g7 ,third party payer ,the term third party payer means an entity that is1 by statute1 contract1 or agreement1 legally responsible for payment of a claim for a health care item or service4 7#f7 ,enforcement 7,a7 ,in general ,in the case of a hospital that fails to comply with this subsection-- 7i7 the ,secretary shall notify such hospital of such failure not later than #cj days after the date on which the ,secretary determines such failure exists2 and 7ii7 not later than #de days after the date of such notification1 the hospital shall complete a corrective action plan to comply with such requirements4 7,b7 ,civil monetary penalty 7i7 ,in general ,in addition to any other enforcement actions or penalties that may apply under subsection 7b77#c7 or another provision of law1 a hospital that has received a notification under subparagraph 7,a77i7 and fails to satisfy the requirement under subparagraph 7,a77ii7 or otherwise comply with the requirements of this subsection by the date that is #ij days after such notification shall be subject to a civil monetary penalty of an amount-- 7,i7 in the case the hospital provides not more than #cj beds 7as determined under section #ahj4ij7;c77#b77;ii77,d7 of title #de1 ,code of ,federal ,regulations1 as in effect on the date of the enactment of this paragraph71 not to exceed #cjj per day that the violation is ongoing as determined by the ,secretary2 and 7,,ii7 in the case the hospital provides more than #cj beds 7as so determined71 equal to-- 7aa7 subject to item 7bb71 #aj per bed per day that the violation is ongoing as determined by the ,secretary1 but for violations occurring before ,january #a1 #bjbd1 not to exceed #e1ejj per each such day2 or 7bb7 in the case such hospital has failed to satisfy the requirement under subparagraph 7,a77ii7 or otherwise comply with the requirements of this subsection for any continuous #a-year period beginning on or after ,january #a1 #bjbd1 and the amount otherwise imposed under item 7aa7 for such failure for such period would be less than #e1jjj1jjj1 an amount not less than #e1jjj1jjj4 7ii7 ,increase authority ,in applying this subparagraph with respect to violations occurring in #bjbe or a subsequent year1 the ,secretary may through notice and comment rulemaking increase any dollar amount applied under this subparagraph by an amount specified by the ,secretary4 7iii7 ,application of certain provisions ,the provisions of section #aabh;,a of the ,social ,security ,act 7other than subsections 7a7 and 7b7 of such section7 shall apply to a civil monetary penalty imposed under clause 7i7 in the same manner as such provisions apply to a civil monetary penalty imposed under subsection 7a7 of such section4 4 7b7 ,publication of list of hospitals 7#a7 ,list of hospitals ,beginning not later than #ij days after the date of enactment of this ,act1 the ,secretary of ,health and ,human ,services 7referred to in this section as the ,secretary7 shall establish and maintain a publicly available list on the website of the ,centers for ,medicare ,medicaid ,services of each hospital with respect to which the ,secretary has conducted a review of such hospital's compliance with the provisions of section #bgah7;e7 of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #cjj;gg-#ah7;e774 ,such list shall include1 with respect to each such hospital that was noncompliant with such provisions1 a specification as to whether such hospital-- 7,a7 has been issued a civil monetary penalty2 7,b7 has received a warning notice2 or 7,c7 has submitted a corrective action plan4 7#b7 ,additions and updates ,in the case of a hospital not included on the list described in paragraph 7#a7 as of the date of the establishment of such list and that is subject to a review of such hospital's compliance with the provisions described in such paragraph after such date1 the ,secretary shall add such hospital to such list1 along with the specifications described in such paragraph1 not later than #a business day after such review occurs4 ,the ,secretary shall update such specifications with respect to any hospital included on such list-- 7,a7 not later than #a business day after any subsequent review of such hospital's compliance with such provisions2 and 7,b7 not later than #a business day after any penalty1 notice1 or request described in paragraph 7#a7 is made with respect to such hospital4 7#c7 ,,foia requests ,any penalty1 notice1 or request described in paragraph 7#a7 shall be subject to public disclosure1 in full and without redaction1 under section #eeb of title #ba1 ,united ,states ,code1 notwithstanding any exemptions or exclusions otherwise available under such section #eeb4 7#d7 ,reports to ,congress ,not later than #a year after the date of enactment of this ,act and each year thereafter1 the ,secretary of ,health and ,human ,services shall submit to ,congress1 and make publicly available1 a report that contains information regarding complaints of alleged violations of law and enforcement activities by the ,secretary under the hospital price transparency rule implementing section #bgah7;e7 of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #cjj;gg-#ah7;e774 ,such report shall be made available to the public on the website of the ,centers for ,medicare ,medicaid ,services4 ,each such report shall include1 with respect to the year involved-- 7,a7 the number of compliance and enforcement inquiries opened by the ,secretary pursuant to such section2 7,b7 the number of notices of noncompliance issued by the ,secretary based on such inquiries2 7,c7 the identity of each hospital entity that received a notice of noncompliance and the nature of the failure giving rise to the ,secretary's determination of noncompliance2 7,d7 the amount of civil monetary penalty assessed against the hospital entity2 7,e7 whether the hospital entity subsequently corrected the noncompliance2 and 7,f7 an analysis of factors contributing to increasing health care costs4 7#e7 ,,gao report ,not later than #a year after the date of enactment of this ,act1 the ,comptroller ,general of the ,united ,states shall submit to the ,committee on ,energy and ,commerce of the ,house of ,representatives and the ,committee on ,health1 ,education1 ,labor1 and ,pensions of the ,senate a report on the compliance and enforcement with the hospital price transparency rule implementing section #bgah7;e7 of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #cjj;gg-#ah7;e774 ,the report shall include recommendations related to-- 7,a7 improving price transparency to patients1 employers1 and the public2 and 7,b7 increased civil monetary penalty amounts to ensure compliance4 7#f7 ,request for information ,not later than ,january #a1 #bjbe1 the ,secretary of ,health and ,human ,services shall issue a public request for information as to the best method through which hospitals may be required to publish quality data 7such as data required to be reported under the ,medicare ,hospital ,compare program7 alongside data required to be reported under section #bgah7;e7 of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #cjj;gg-#ah7;e774 7c7 ,ensuring accessibility through implementation ,in implementing the amendments made by this section1 the ,secretary of ,health and ,human ,services shall through rulemaking ensure that a hospital submitting charges and information pursuant to such amendments takes reasonable steps 7as specified by the ,secretary7 to ensure the accessibility of such charges and information to individuals with limited ,english proficiency4 ,such steps may include the hospital's provision of interpretation services or the hospital's provision of translations of charges and information4 #ajb4 ,strengthening health insurer transparency requirements 7a7 ,transparency in coverage ,section #acaa7;e77#c77;,c7 of the ,patient ,protection and ,affordable ,care ,act 7#db ,u4,s4,c4 #ahjca7;e77#c77;,c77 is amended-- 7#a7 by striking ,the ,exchange and inserting the following3 7i7 ,in general ,the ,exchange 2 7#b7 in clause 7i71 as inserted by paragraph 7#a7-- 7,a7 by striking participating provider and inserting provider2 7,b7 by inserting shall include the information specified in clause 7ii7 and after such information2 7,c7 by striking an ,internet website and inserting a self-service tool that meets the requirements of clause 7iii72 and 7,d7 by striking and such other and all that follows through the period and inserting or1 at the option such individual1 through a paper or phone disclosure 7as selected by such individual and provided at no cost to such individual7 that meets such requirements as the ,secretary may specify42 and 7#c7 by adding at the end the following new clauses3 7ii7 ,specified information ,for purposes of clause 7i71 the information specified in this clause is1 with respect to an item or service for which benefits are available under a health plan furnished by a health care provider1 the following3 7,i7 ,if such provider is a participating provider with respect to such item or service1 the in-network rate 7as defined in subparagraph 7,f77 for such item or service4 7,,ii7 ,if such provider is not described in subclause 7,i71 the maximum allowed amount for such item or service4 7,,iii7 ,the amount of cost sharing 7including deductibles1 copayments1 and coinsurance7 that the individual will incur for such item or service 7which1 in the case such item or service is to be furnished by a provider described in subclause 7,,ii71 shall be calculated using the maximum amount described in such subclause74 7,,iv7 ,the amount the individual has already accumulated with respect to any deductible or out of pocket maximum under the plan 7broken down1 in the case separate deductibles or maximums apply to separate individuals enrolled in the plan1 by such separate deductibles or maximums1 in addition to any cumulative deductible or maximum74 7,v7 ,in the case such plan imposes any frequency or volume limitations with respect to such item or service 7excluding medical necessity determinations71 the amount that such individual has accrued towards such limitation with respect to such item or service4 7,,vi7 ,any prior authorization1 concurrent review1 step therapy1 fail first1 or similar requirements applicable to coverage of such item or service under such plan4 7iii7 ,self-service tool ,for purposes of clause 7i71 a self-service tool established by a health plan meets the requirements of this clause if such tool-- 7,i7 is based on an internet website2 7,,ii7 provides for real-time responses to requests described in such clause2 7,,iii7 is updated in a manner such that information provided through such tool is timely and accurate2 7,,iv7 allows such a request to be made with respect to an item or service furnished by-- 7aa7 a specific provider that is a participating provider with respect to such item or service2 7bb7 all providers that are participating providers with respect to such plan and such item or service2 or 7cc7 a provider that is not described in item 7bb72 and 7,v7 provides that such a request may be made with respect to an item or service through use of the billing code for such item or service or through use of a descriptive term for such item or service4 ,the ,secretary may require such tool1 as a condition of complying with subclause 7,v71 to link multiple billing codes to a single descriptive term if the ,secretary determines that the billing codes to be so linked correspond to items and services4 4 7b7 ,disclosure of additional information ,section #acaa7;e77#c7 of the ,patient ,protection and ,affordable ,care ,act 7#db ,u4,s4,c4 #ahjca7;e77#c77 is amended by adding at the end the following new subparagraphs3 7,e7 ,rate and payment information 7i7 ,in general ,not later than ,january #a1 #bjbe1 and every #c months thereafter1 each health plan shall submit to the ,exchange1 the ,secretary1 the ,state insurance commissioner1 and make available to the public1 the rate and payment information described in clause 7ii7 in accordance with clause 7iii74 7ii7 ,rate and payment information described ,for purposes of clause 7i71 the rate and payment information described in this clause is1 with respect to a health plan1 the following3 7,i7 ,with respect to each item or service for which benefits are available under such plan1 the in-network rate in effect as of the date of the submission of such information with each provider 7identified by national provider identifier7 that is a participating provider with respect to such item or service1 other than such a rate in effect with a provider that1 during the #a-year period ending on such date1 submitted fewer than #aj claims for such item or service to such plan4 7,,ii7 ,with respect to each drug 7identified by national drug code7 for which benefits are available under such plan1 the average amount paid by such plan 7net of rebates1 discounts1 and price concessions7 for such drug dispensed or administered during the #ij-;day period beginning #ahj days before such date of submission to each provider that was a participating provider with respect to such drug1 broken down by each such provider 7identified by national provider identifier71 other than such an amount paid to a provider that1 during such period1 submitted fewer than #bj claims for such drug to such plan4 7,,iii7 ,with respect to each item or service for which benefits are available under such plan1 the amount billed1 and the amount allowed by the plan1 for each such item or service furnished during the #ij-;day period specified in subclause 7,,ii7 by a provider that was not a participating provider with respect to such item or service1 broken down by each such provider 7identified by national provider identifier71 other than items and services with respect to which fewer than #bj claims for such item or service were submitted to such plan during such period4 7iii7 ,manner of submission ,rate and payment information required to be submitted and made available under this subparagraph shall be so submitted and so made available in #c separate machine-readable files corresponding to the information described in each of subclauses 7,i7 through 7,,iii7 of clause 7ii7 that meet such requirements as specified by the ,secretary through rulemaking4 ,such requirements shall ensure that such files are limited to an appropriate size1 are made available in a widely-available format that allows for information contained in such files to be compared across health plans1 and are accessible to individuals at no cost and without the need to establish a user account or provider other credentials4 7iv7 ,user guide ,each health plan shall make available to the public instructions written in plain language explaining how individuals may search for information described in clause 7ii7 in files submitted in accordance with clause 7iii74 7,f7 ,definitions ,in this paragraph3 7i7 ,participating provider ,the term participating provider has the meaning given such term in section #bgii;,a-#a of the ,public ,health ,service ,act4 7ii7 ,in-network rate ,the term in-network rate means1 with respect to a health plan and an item or service furnished by a provider that is a participating provider with respect to such plan and item or service1 the contracted rate in effect between such plan and such provider for such item or service4 4 7c7 ,reports 7#a7 ,compliance ,not later than ,january #a1 #bjbe1 the ,comptroller ,general of the ,united ,states shall submit to ,congress a report containing-- 7,a7 an analysis of health plan compliance with the amendments made by this section2 7,b7 an analysis of enforcement of such amendments by the ,secretaries of ,health and ,human ,services1 ,labor1 and the ,treasury2 7,c7 recommendations relating to improving such enforcement2 and 7,d7 recommendations relating to improving public disclosure1 and public awareness1 of information required to be made available by such plans pursuant to such amendments4 7#b7 ,prices ,not later than ,january #a1 #bjbh1 the ,comptroller ,general of the ,united ,states shall submit to ,congress a report containing an assessment of differences in negotiated prices 7and any trends in such prices7 in the private market between-- 7,a7 rural and urban areas2 7,b7 the individual1 small group1 and large group markets2 7,c7 consolidated and nonconsolidated health care provider areas 7as specified by the ,secretary72 7,d7 nonprofit and for-profit hospitals2 7,e7 nonprofit and for-profit insurers2 and 7,f7 insurers serving local or regional areas and insurers serving multistate or national areas4 7d7 ,ensuring accessibility through implementation ,in implementing the amendments made by this section1 the ,secretary shall through rulemaking ensure that any entity making available information pursuant to such amendments takes reasonable steps 7as specified by the ,secretary7 to ensure the accessibility of such to individuals with limited ,english proficiency4 ,such steps may include the entity's provision of interpretation services or of translations of such information4 7e7 ,effective date 7#a7 ,in general ,the amendments made by subsection 7a7 shall apply beginning ,january #a1 #bjbe4 7#b7 ,continued applicability of rules for previous years ,nothing in the amendments made by this section may be construed as affecting the applicability of the rule entitled ,transparency in ,coverage published by the ,department of the ,treasury1 the ,department of ,labor1 and the ,department of ,health and ,human ,services on ,november #ab1 #bjbj 7#he ,fed4 ,reg4 #gbaeh7 before ,january #a1 #bjbe4 #ajc4 ,requiring a separate identification number and an attestation for each off-campus outpatient department of a provider ,section #ahcc7t7 of the ,social ,security ,act 7#db ,u4,s4,c4 #aciel7t77 is amended by adding at the end the following new paragraph3 7#bc7 ,use of unique health identifiers2 attestation 7,a7 ,in general ,no payment may be made under this subsection 7or under an applicable payment system pursuant to paragraph 7#ba77 for items and services furnished on or after ,january #a1 #bjbf1 by an off-campus outpatient department of a provider 7as defined in subparagraph 7,c77 unless-- 7i7 such department has obtained1 and such items and services are billed under1 a standard unique health identifier for health care providers 7as described in section #aagc7;b77 that is separate from such identifier for such provider2 and 7ii7 such provider has submitted to the ,secretary1 during the #b-year period ending on the date such items and services are so furnished1 an attestation that such department is compliant with the requirements described in section #dac4fe of title #db1 ,code of ,federal ,regulations 7or a successor regulation74 7,b7 ,process for submission and review ,not later than #a year after the date of enactment of this paragraph1 the ,secretary shall1 through notice and comment rulemaking1 establish a process for each provider with an off-campus outpatient department of a provider to submit an attestation pursuant to subparagraph 7,a77ii71 and for the ,secretary to review each such attestation and determine1 through site visits or through remote audits 7as determined appropriate by the ,secretary71 whether such department is compliant with the requirements described in such subparagraph4 7,c7 ,off-campus outpatient department of a provider defined ,for purposes of this paragraph1 the term off-campus outpatient department of a provider means a department of a provider 7as defined in section #dac4fe of title #db1 ,code of ,federal ,regulations1 or any successor regulation7 that is not located-- 7i7 on the campus 7as defined in such section7 of such provider2 or 7ii7 within the distance 7described in such definition of campus7 from a remote location of a hospital facility 7as defined in such section74 4 #ajd4 ,mandatory reporting with respect to certain health-related ownership information ,part ,a of title ,,xi of the ,social ,security ,act 7#db ,u4,s4,c4 #acja et seq47 is amended by adding at the end the following new section3 #aaej;,d4 ,mandatory reporting with respect to certain health-related ownership information 7a7 ,mandatory reporting with respect certain health-,related ownership information 7#a7 ,initial report ,not later than ,january #a1 #bjbe 7or in the case of a specified entity formed after ,january #a1 #bjbe1 within #fj days of becoming a specified entity71 each specified entity 7as defined in subsection 7f77#e77 shall submit to the ,secretary1 in a form and manner specified by the ,secretary1 a report containing the following information3 7,a7 ,data on mergers1 acquisitions1 and changes in ownership with respect to such specified entity for the previous #a-year period4 7,b7 ,in the case that a specified entity is1 or includes1 a hospital1 the additional information described in subsection 7b74 7,c7 ,as applicable1 the name1 address1 and business structure of the parent company of such specified entity 7including the tax status of such parent company71 as of the date of the submission of this report4 7,d7 ,any other information with respect to ownership of a specified entity1 as determined by the ,secretary4 7#b7 ,subsequent reports ,not later than #a year after submitting the report under paragraph 7#a71 and annually thereafter1 each specified entity shall submit to the ,secretary an updated report1 including-- 7,a7 7i7 data on mergers1 acquisitions1 and changes in ownership with respect to such entities for the previous #a-year period2 and 7ii7 any other information with respect to ownership of a specified entity1 as determined by the ,secretary2 and 7,b7 in the case that a specified entity is1 or includes1 a hospital1 the additional information described in subsection 7b74 7b7 ,additional information submitted by certain specified entities ,for purposes of paragraphs 7#a77;,b7 and 7#b77;,b7 of subsection 7a71 with respect to a specified entity that is1 or includes1 a hospital1 the information described in this subsection is the following information with respect to the previous #a-year period3 7#a7 ,the business structure of the specified entity1 including the business type and the tax status of such entity4 7#b7 ,the average debt-to-earnings ratio of the specified entity4 7#c7 ,the average amount of debt incurred-- 7,a7 by the hospital2 and 7,b7 by the entire specified entity4 7#d7 ,information with respect to real estate leases and purchases for property used1 or intended to be used1 to furnish or otherwise support the provision of health care services4 7#e7 ,in the case of a non-profit hospital1 a subsidiary of a non-profit hospital1 or a #eja7;c77#c7 entity that shares common ownership with a non-profit hospital1 capital gains investments 7disaggregated by the type of investment7 and any taxes paid on such gains from such investments4 7#f7 ,as applicable1 information with respect to the parent company of such specified entity4 7c7 ,public reporting ,not later than ,january #a1 #bjbg1 and annually thereafter1 the ,secretary shall post on a publicly available website of the ,department of ,health and ,human ,services a report with respect to the previous #a-year period1 including-- 7#a7 the number of specified entities reporting for such year1 disaggregated by the business structure of each specified entity2 7#b7 the number of owners of each specified entity2 7#c7 any change in ownership for each specified entity2 7#d7 any change in the tax status of a specified entity2 7#e7 an analysis of trends in horizontal and vertical consolidation1 disaggregated by business structure and provider type2 and 7#f7 as applicable1 the name1 address1 and business structure of the parent company of such specified entity 7including the business type and the tax status of such parent company74 7d7 ,audits ,the ,secretary shall conduct an annual audit consisting of a random sample of specified entities to verify compliance with the requirements of this section and the accuracy of information submitted pursuant to this section4 7e7 ,penalty for failure ,to report ,if a specified entity fails to provide a complete report under subsection 7a71 or submits a report containing false information1 such entity shall be subject to a civil monetary penalty of not more than #e1jjj1jjj for each such report not provided or containing false information4 ,such penalty shall be imposed and collected in the same manner as civil money penalties under subsection 7a7 of section #aabh;,a are imposed and collected under that section4 7f7 ,inapplicability of ,paperwork ,reduction ,act ,chapter #ce of title #dd1 ,united ,states ,code1 shall not apply to collections of information made under this section4 7g7 ,definitions ,in this section3 7#a7 ,health plan ,the term health plan has the meaning given such term in section #aabh;,c7c74 7#b7 ,hospital ,the term hospital has the meaning given such term in section #ahfa7;e74 7#c7 ,independent freestanding emergency department ,the term independent freestanding emergency department has the meaning given such term in section #bgii;,a-#a7;a77#c77;,d7 of the ,public ,health ,service ,act4 7#d7 ,private equity company ,the term private equity company means a publicly-traded or non-publicly traded company that collects capital investments from individuals or entities and purchases an ownership share of a provider of services 7as defined in section #ahfa7u774 7#e7 ,specified entity ,the term specified entity means-- 7,a7 a hospital2 7,b7 a physician-owned physician practice with more than #be physicians for a year2 7,c7 a physician practice owned by a hospital1 a health plan1 a private equity company1 or a venture capital firm2 7,d7 an ambulatory surgical center meeting the standards specified under section #ahcb7;a77#b77;,f77i72 or 7,e7 an independent freestanding emergency department4 7#f7 ,venture capital fund ,the term venture capital fund has the meaning given such term in section #bge4bjc7l7-#a of title #ag1 ,code of ,federal ,regulations4 4 #aje4 ,increasing price transparency of clinical diagnostic laboratory tests under the ,medicare program ,section #ahdf of the ,social ,security ,act 7#db ,u4,s4,c4 #aciew-#b7 is amended-- 7#a7 in the header1 by inserting and additional requirements after sanctions2 and 7#b7 by adding at the end the following new subsection3 7c7 ,price transparency requirement 7#a7 ,in general ,beginning ,january #a1 #bjbe1 each provider of services or supplier that is available to furnish any specified clinical diagnostic laboratory test under this title shall-- 7,a7 make publicly available on an internet website the information described in paragraph 7#b7 with respect to each such specified clinical diagnostic laboratory test that such provider or supplier is so available to furnish2 and 7,b7 ensure that such information is updated not less frequently than annually4 7#b7 ,information described ,for purposes of paragraph 7#a71 the information described in this paragraph is1 with respect to a provider of services or supplier and a specified clinical diagnostic laboratory test1 the following3 7,a7 ,the discounted cash price for such test 7or1 if no such price exists1 the gross charge for such test74 7,b7 ,the deidentified minimum negotiated rate in effect between such provider or supplier and any group health plan or group or individual health insurance coverage for such test4 7,c7 ,the deidentified maximum negotiated rate in effect between such provider or supplier and any such plan or coverage for such test4 7#c7 ,inclusion of ancillary services ,any price or rate for a specified clinical diagnostic laboratory test available to be furnished by a provider of services or supplier made publicly available in accordance with paragraph 7#a7 shall include the price or rate 7as applicable7 for any ancillary item or service 7such as specimen collection services7 that would normally be furnished by such provider or supplier as part of such test1 as specified by the ,secretary4 7#d7 ,enforcement 7,a7 ,in general ,in the case that the ,secretary determines that a provider of services or supplier is not in compliance with paragraph 7#a7-- 7i7 not later than #cj days after such determination1 the ,secretary shall notify such provider or supplier of such determination2 7ii7 not later than #ij days after such notification is sent1 such provider or supplier shall complete a corrective action plan to comply with such paragraph and submit such plan to the ,secretary2 and 7iii7 if such provider or supplier continues to fail to comply with such paragraph after the date that is #ij days after such notification is sent1 the ,secretary may impose a civil monetary penalty in an amount not to exceed #cjj for each day 7beginning with the date that is #ia days after such notification was sent7 during which such failure is ongoing4 7,b7 ,application of certain provisions ,the provisions of section #aabh;,a 7other than subsections 7a7 and 7b7 of such section7 shall apply to a civil monetary penalty imposed under this paragraph in the same manner as such provisions apply to a civil monetary penalty imposed under subsection 7a7 of such section4 7#e7 ,definitions ,in this subsection3 7,a7 ,group health plan2 group health insurance coverage2 individual health insurance coverage ,the terms group health plan1 group health insurance coverage1 and individual health insurance coverage have the meaning given such terms in section #bgia of the ,public ,health ,service ,act4 7,b7 ,specified clinical diagnostic laboratory test the term specified clinical diagnostic laboratory test means a clinical diagnostic laboratory test that is included on the list of shoppable services specified by the ,centers for ,medicare ,medicaid ,services 7as described in section #ahj4fj of title #db1 ,code of ,federal ,regulations 7or a successor regulation774 4 #ajf4 ,promoting transparency of common ownership interests under parts ,c and ,d of the ,medicare program 7a7 ,medicare ,advantage ,section #aheg7;e7 of the ,social ,security ,act 7#db ,u4,s4,c4 #aciew-#bg7;e77 is amended by adding at the end the following new paragraph3 7#f7 ,required disclosure of certain information relating to health care provider ownership 7,a7 ,in general ,for plan years beginning on or after ,january #a1 #bjbe1 a contract under this section with an ,,ma organization shall require the organization to report to the ,secretary1 not later than #a year after the last day of such plan year1 the information described in subparagraph 7,b7 with respect to such plan year4 7,b7 ,information described ,for purposes of subparagraph 7,a71 the information described in this subparagraph is1 with respect to an ,,ma organization and a plan year1 the following3 7i7 ,the number of items and services furnished during such plan year by each specified provider 7as defined in subparagraph 7,c77 for which payment was made by such organization4 7ii7 ,the number of items and services furnished during such plan year by providers of services or suppliers not described in clause 7i7 for which payment was made by such organization4 7iii7 ,the average per-enrollee number of qualifying diagnoses 7as defined in subparagraph 7,c77 made during such plan year by specified providers 7including through chart reviews and health risk assessments7 with respect to individuals enrolled under an ,,ma plan offered by such organization1 broken down by site of service of such providers1 as specified by the ,secretary4 7iv7 ,the average per-enrollee number of qualifying diagnoses made during such plan year by providers of services and suppliers not described in clause 7iii7 7including through such reviews and assessments7 with respect to such individuals1 broken down by site of service of such providers4 7v7 ,the average risk score 7as calculated under the methodology described in subparagraph 7,c77i77 for such an individual for such plan year who received items and services from a specified provider during such plan year4 7vi7 ,the average risk score for such an individual for such plan year who did not receive items and services from a specified provider during such plan year4 7vii7 ,the average risk score for such an individual for such plan year who received a health risk assessment from an assessment entity that was a specified assessment entity during such plan year4 7viii7 ,the average risk score for such an individual for such plan year who received a health risk assessment from an assessment entity that was not a specified assessment entity during such plan year4 7ix7 ,the number of prior authorization requests for an item or service submitted to such organization during such plan year1 the number of such requests that were approved1 the number of such requests that were denied1 and the number of such denied requests that were subsequently appealed and then approved1 broken down by whether the entity proposing to furnish such item or service was a specified provider or not a specified provider4 7x7 ,the total amount of incentive-based payments made to1 and the total amount of shared losses recoupments collected from1 specified providers during such plan year4 7xi7 ,the total amount of incentive-based payments made to1 and the total amount of shared losses recoupments collected from1 providers of services and suppliers not described in clause 7x7 during such plan year4 7xii7 ,the allowed amount1 and the amount of cost sharing imposed1 with respect to each item and service furnished during such plan year by specified providers paid by such organization4 7xiii7 ,the allowed amount1 and the amount of cost sharing imposed1 with respect to each item and service furnished during such plan year by providers of services and suppliers not described in clause 7xii7 paid by such organization4 7xiv7 ,for each ,,ma plan offered by such organization during such plan year-- 7,i7 the total amount of payments made under section #ahec7;a77#a7 to such organization for coverage of individuals under such plan1 and the total amount of payments made by such individuals to such organization for coverage under such plan2 7,,ii7 the total amount expended under such plan as payment for items and services furnished by each specified provider during such year2 7,,iii7 the total amount expended under such plan as payment for items and services furnished by providers of services or suppliers not described in subclause 7,,ii7 during such year2 7,,iv7 the medical loss ratio under such plan with respect to individuals furnished an item or service from a specified provider during such year2 and 7,v7 the medical loss ratio under such plan with respect to individuals not described in subclause 7,,iv74 7,c7 ,definitions ,in this paragraph3 7i7 ,assessment entity ,the term assessment entity means an entity with a focus on furnishing in-home medical assessments1 as specified by the ,secretary4 7ii7 ,qualifying diagnosis ,the term qualifying diagnosis means1 with respect to an individual1 a diagnosis that is taken into account in calculating a risk score for such individual under the risk adjustment methodology established by the ,secretary pursuant to section #ahec7;a77#c74 7iii7 ,specified assessment entity ,the term specified assessment entity means1 with respect to an ,,ma organization and a plan year1 an assessment entity with respect to which such organization 7or any person with an ownership or control interest 7as defined in section #aabd7;a77#c77 in such organization7 is a person with an ownership or control interest 7as so defined74 7iv7 ,specified provider ,the term specified provider means1 with respect to an ,,ma organization and a plan year1 a provider of services or supplier with respect to which such organization 7or any person with an ownership or control interest 7as defined in section #aabd7;a77#c77 in such organization7 is a person with an ownership or control interest 7as so defined74 7,d7 ,nonapplication of ,paperwork ,reduction ,act ,chapter #ce of title #dd1 ,united ,states ,code1 shall not apply to information collected under this paragraph4 4 7b7 ,pharmacy benefit manager and pharmacy information ,section #ahfj;,d-#ab7;b7 of the ,social ,security ,act 7#db ,u4,s4,c4 #aciew-#aab7;b77 is amended by adding at the end the following new paragraphs3 7#i7 ,provision of information relating to pharmacy ownership 7,a7 ,in general ,for plan years beginning on or after ,january #a1 #bjbe1 a contract entered into under this part with a ,,pdp sponsor shall require the sponsor to report to the ,secretary1 not later than #a year after the last day of such plan year1 the information described in subparagraph 7,b7 with respect to such plan year4 7,b7 ,information described ,for purposes of subparagraph 7,a71 the information described in this subparagraph is1 for each prescription drug plan offered by a ,,pdp sponsor for a plan year1 the following3 7i7 ,the negotiated price for each covered part ,d drug for which benefits are available under such plan for each network pharmacy 7including an identification of whether each such pharmacy is a specified pharmacy74 7ii7 ,the average per-drug amount of direct and indirect remuneration paid by specified pharmacies for such covered part ,d drugs dispensed during such plan year under such plan4 7iii7 ,the average per-drug amount of direct and indirect remuneration paid by pharmacies not described in clause 7ii7 for such covered part ,d drugs dispensed during such plan year under such plan4 7,c7 ,definitions ,in this paragraph3 7i7 ,direct and indirect remuneration ,the term direct and indirect remuneration has the meaning given such term in section #dbc4cjh of title #db1 ,code of ,federal ,regulations 7or any successor regulation74 7ii7 ,network pharmacy ,the term network pharmacy has the meaning given such term in section #dbc4ajj of title #db1 ,code of ,federal ,regulations 7or any successor regulation74 7iii7 ,negotiated price ,the negotiated price for a covered part ,d drug shall take into account all negotiated price concessions1 such as discounts1 direct or indirect subsidies1 rebates1 and direct or indirect remunerations1 for such drug1 and include any dispensing fee for such drug4 7iv7 ,specified pharmacy ,the term specified pharmacy means1 with respect to an ,,pdp sponsor and a plan year1 a pharmacy with respect to which such sponsor 7or any person with an ownership or control interest 7as defined in section #aabd7;a77#c77 in such sponsor7 is a person with an ownership or control interest 7as so defined74 7,d7 ,nonapplication of ,paperwork ,reduction ,act ,chapter #ce of title #dd1 ,united ,states ,code1 shall not apply to information collected under this paragraph4 7#aj7 ,provision of information by pharmacy benefit managers 7,a7 ,in general ,for plan years beginning on or after ,january #a1 #bjbe1 a contract entered into under this part with a ,,pdp sponsor shall prohibit such sponsor from entering into a contract with a specified pharmacy benefit manager for purposes of performing any service with respect to covered part ,d drugs dispensed under any prescription drug plan offered by such sponsor for such plan year unless such manager agrees to report to the ,secretary1 not later than #a year after the last day of such plan year1 the information described in subparagraph 7,b7 with respect to each prescription drug plan for which such manager is providing any such service during such plan year1 regardless of the sponsor of such plan4 7,b7 ,information described ,for purposes of subparagraph 7,a71 the information described in this subparagraph is1 with respect to a pharmacy benefit manager performing services under a prescription drug plan for a plan year1 the following3 7i7 ,with respect to the total amount of pharmacy and manufacturer rebates collected by such manager 7or collected on behalf of such plan by any other entity with a contract in effect with such manager for such collection7 for all covered part ,d drugs dispensed under such plan during such plan year-- 7,i7 the total amount of such rebates passed through to the ,,pdp sponsor of such plan2 and 7,,ii7 the total amount of such rebates retained by such manager or such other entities4 7ii7 ,the total amount paid by such manager to pharmacies for drugs furnished under such plan during such plan year4 7iii7 ,the total amount of payments made by such sponsor to such manager as reimbursement for such manager's payments described in clause 7ii74 7iv7 ,the total amount of payments made by such sponsor to such manager as fees for services furnished by such manager with respect to such plan for such plan year 7not including payments described in clause 7iii774 7v7 ,the total amount of administrative costs incurred by such manager for furnishing such services under such plan for such plan year4 7vi7 ,a specification as to whether such manager is a specified pharmacy benefit manager with respect to the ,,pdp sponsor of such plan4 7,c7 ,definition ,in this paragraph1 the term specified pharmacy benefit manager means1 with respect to an ,,pdp sponsor and a plan year1 a pharmacy benefit manager with respect to which such sponsor 7or any person with an ownership or control interest 7as defined in section #aabd7;a77#c77 in such sponsor7 is a person with an ownership or control interest 7as so defined74 4 7c7 ,encounter data ,section #ahei of the ,social ,security ,act 7#db ,u4,s4,c4 #aciew-#bh7 is amended by adding at the end the following new subsection3 7j7 ,inclusion of certain information in encounter data 7#a7 ,in general ,in the case of any encounter data submitted by a ,medicare ,advantage plan with respect to an item or service furnished to an individual under such plan during a plan year beginning on or after ,january #a1 #bjbe1 the ,secretary shall require that such data include-- 7,a7 the allowed amount for such item or service2 7,b7 the amount of cost sharing 7including deductibles1 copayments1 and coinsurance7 imposed for such item or service2 7,c7 in the case such individual was furnished1 during such plan year before such item or service was so furnished1 an at-home health risk assessment from a specified assessment entity1 an indicator that such individual was so furnished such an assessment by such an entity2 and 7,d7 in the case such individual was furnished1 during such plan year before such item or service was so furnished1 an at-home health risk assessment from an assessment entity not described in subparagraph 7,c71 an indicator 7distinct from the indicator described in such subparagraph7 that such individual was so furnished such an assessment by such an entity4 7#b7 ,definitions ,for purposes of this subsection1 the terms assessment entity and specified assessment entity have the meaning given such terms in section #aheg7;e77#f74 4 7d7 ,med,p,a,c report ,not later than ,december #ca1 #bjbg1 and every #b years thereafter1 the ,medicare ,payment ,advisory ,commission shall submit to ,congress a report on the effects of vertical integration in the health care sector on the ,medicare program4 ,such report shall include an analysis of the effects of entities such as health care providers1 pharmacies1 ,,pdp sponsors1 ,medicare ,advantage organizations1 and pharmacy benefit managers that were previously under separate ownership from one another coming under common ownership4 7e7 ,publication ,not later than ,january #a1 #bjbg1 the ,secretary of ,health and ,human ,services shall establish a process under which information submitted to the ,secretary pursuant to the amendments made by subsections 7a7 and 7b7 is publicly disclosed4 ,such process shall ensure that any information so disclosed does not identify a specific drug manufacturer1 provider of services or supplier1 pharmacy1 pharmacy benefit manager1 or any price charged with respect to a particular drug4 #ajg4 ,oversight of pharmacy benefits manager services 7a7 ,,phsa ,title ,,xxvii of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #cjj;gg et seq47 is amended-- 7#a7 in part ,d 7#db ,u4,s4,c4 #cjj;gg-#aaa et seq471 by adding at the end the following new section3 #bgii;,a-#aa4 ,oversight of pharmacy benefits manager services 7a7 ,in general ,for plan years beginning on or after ,january #a1 #bjbe1 a group health plan or health insurance issuer offering group health insurance coverage or an entity or subsidiary providing pharmacy benefits management services on behalf of such a plan or issuer shall not enter into a contract with a drug manufacturer1 distributor1 wholesaler1 subcontractor1 rebate aggregator1 or any associated third party that limits the disclosure of information to plan sponsors in such a manner that prevents the plan or issuer1 or an entity or subsidiary providing pharmacy benefits management services on behalf of a plan or issuer1 from making the reports described in subsection 7b74 7b7 ,reports 7#a7 ,in general ,for plan years beginning on or after ,january #a1 #bjbe1 not less frequently than annually1 a health insurance issuer offering group health insurance coverage or an entity providing pharmacy benefits management services on behalf of a group health plan or an issuer providing group health insurance coverage shall submit to the plan sponsor 7as defined in section #c7af77;,b7 of the ,employee ,retirement ,income ,security ,act of #aigd7 of such group health plan or health insurance coverage a report in accordance with this subsection and make such report available to the plan sponsor in a machine-readable format4 ,each such report shall include1 with respect to the applicable group health plan or health insurance coverage-- 7,a7 as applicable1 information collected from drug manufacturers by such issuer or entity on the total amount of copayment assistance dollars paid1 or copayment cards applied1 that were funded by the drug manufacturer with respect to the participants and beneficiaries in such plan or coverage2 7,b7 a list of each drug covered by such plan1 issuer1 or entity providing pharmacy benefits management services that was dispensed during the reporting period1 including1 with respect to each such drug during the reporting period-- 7i7 the brand name1 chemical entity1 and ,national ,drug ,code2 7ii7 the number of participants and beneficiaries for whom the drug was filled during the plan year1 the total number of prescription fills for the drug 7including original prescriptions and refills71 and the total number of dosage units of the drug dispensed across the plan year1 including whether the dispensing channel was by retail1 mail order1 or specialty pharmacy2 7iii7 the wholesale acquisition cost1 listed as cost per days supply and cost per pill1 or in the case of a drug in another form1 per dose2 7iv7 the total out-of-pocket spending by participants and beneficiaries on such drug1 including participant and beneficiary spending through copayments1 coinsurance1 and deductibles2 and 7v7 for any drug for which gross spending of the group health plan or health insurance coverage exceeded #aj1jjj during the reporting period-- 7,i7 a list of all other drugs in the same therapeutic category or class1 including brand name drugs and biological products and generic drugs or biosimilar biological products that are in the same therapeutic category or class as such drug2 and 7,,ii7 the rationale for preferred formulary placement of such drug in that therapeutic category or class1 if applicable2 7,c7 a list of each therapeutic category or class of drugs that were dispensed under the health plan or health insurance coverage during the reporting period1 and1 with respect to each such therapeutic category or class of drugs1 during the reporting period-- 7i7 total gross spending by the plan1 before manufacturer rebates1 fees1 or other manufacturer remuneration2 7ii7 the number of participants and beneficiaries who filled a prescription for a drug in that category or class2 7iii7 if applicable to that category or class1 a description of the formulary tiers and utilization mechanisms 7such as prior authorization or step therapy7 employed for drugs in that category or class2 7iv7 the total out-of-pocket spending by participants and beneficiaries1 including participant and beneficiary spending through copayments1 coinsurance1 and deductibles2 and 7v7 for each therapeutic category or class under which #c or more drugs are included on the formulary of such plan or coverage-- 7,i7 the amount received1 or expected to be received1 from drug manufacturers in rebates1 fees1 alternative discounts1 or other remuneration-- 7aa7 that has been paid1 or is to be paid1 by drug manufacturers for claims incurred during the reporting period2 or 7bb7 that is related to utilization of drugs1 in such therapeutic category or class2 7,,ii7 the total net spending1 after deducting rebates1 price concessions1 alternative discounts or other remuneration from drug manufacturers1 by the health plan or health insurance coverage on that category or class of drugs2 and 7,,iii7 the net price per course of treatment or single fill1 such as a #cj-;day supply or #ij-;day supply1 incurred by the health plan or health insurance coverage and its participants and beneficiaries1 after manufacturer rebates1 fees1 and other remuneration for drugs dispensed within such therapeutic category or class during the reporting period2 7,d7 total gross spending on prescription drugs by the plan or coverage during the reporting period1 before rebates and other manufacturer fees or remuneration2 7,e7 total amount received1 or expected to be received1 by the health plan or health insurance coverage in drug manufacturer rebates1 fees1 alternative discounts1 and all other remuneration received from the manufacturer or any third party1 other than the plan sponsor1 related to utilization of drug or drug spending under that health plan or health insurance coverage during the reporting period2 7,f7 the total net spending on prescription drugs by the health plan or health insurance coverage during the reporting period2 and 7,g7 amounts paid directly or indirectly in rebates1 fees1 or any other type of remuneration to brokers1 consultants1 advisors1 or any other individual or firm who referred the group health plan's or health insurance issuer's business to the pharmacy benefits manager4 7#b7 ,privacy requirements ,health insurance issuers offering group health insurance coverage and entities providing pharmacy benefits management services on behalf of a group health plan shall provide information under paragraph 7#a7 in a manner consistent with the privacy1 security1 and breach notification regulations promulgated under section #bfd7;c7 of the ,health ,insurance ,portability and ,accountability ,act of #aiif1 and shall restrict the use and disclosure of such information according to such privacy regulations4 7#c7 ,disclosure and redisclosure 7,a7 ,limitation to business associates ,a group health plan receiving a report under paragraph 7#a7 may disclose such information only to business associates of such plan as defined in section #afj4ajc of title #de1 ,code of ,federal ,regulations 7or successor regulations74 7,b7 ,clarification regarding public disclosure of information ,nothing in this section prevents a health insurance issuer offering group health insurance coverage or an entity providing pharmacy benefits management services on behalf of a group health plan from placing reasonable restrictions on the public disclosure of the information contained in a report described in paragraph 7#a71 except that such issuer or entity may not restrict disclosure of such report to the ,department of ,health and ,human ,services1 the ,department of ,labor1 the ,department of the ,treasury1 the ,comptroller ,general of the ,united ,states1 or applicable ,state agencies4 7,c7 ,limited form of report ,the ,secretary shall define through rulemaking a limited form of the report under paragraph 7#a7 required of plan sponsors who are drug manufacturers1 drug wholesalers1 or other direct participants in the drug supply chain1 in order to prevent anti-competitive behavior4 7#d7 ,report to ,,gao ,a health insurance issuer offering group health insurance coverage or an entity providing pharmacy benefits management services on behalf of a group health plan shall submit to the ,comptroller ,general of the ,united ,states each of the first #d reports submitted to a plan sponsor under paragraph 7#a7 with respect to such coverage or plan1 and other such reports as requested1 in accordance with the privacy requirements under paragraph 7#b71 the disclosure and redisclosure standards under paragraph 7#c71 the standards specified pursuant to paragraph 7#e71 and such other information that the ,comptroller ,general determines necessary to carry out the study under section #b7;d7 of the ,pharmacy ,benefits ,manager ,accountability ,act4 7#e7 ,standard format ,not later than ,june #a1 #bjbc1 the ,secretary shall specify through rulemaking standards for health insurance issuers and entities required to submit reports under paragraph 7#d7 to submit such reports in a standard format4 7c7 ,enforcement 7#a7 ,in general ,the ,secretary1 in consultation with the ,secretary of ,labor and the ,secretary of the ,treasury1 shall enforce this section4 7#b7 ,failure to provide timely information ,a health insurance issuer or an entity providing pharmacy benefits management services that violates subsection 7a7 or fails to provide information required under subsection 7b7 shall be subject to a civil monetary penalty in the amount of #aj1jjj for each day during which such violation continues or such information is not disclosed or reported4 7#c7 ,false information ,a health insurance issuer or entity providing pharmacy benefits management services that knowingly provides false information under this section shall be subject to a civil money penalty in an amount not to exceed #ajj1jjj for each item of false information4 ,such civil money penalty shall be in addition to other penalties as may be prescribed by law4 7#d7 ,procedure ,the provisions of section #aabh;,a of the ,social ,security ,act1 other than subsection 7a7 and 7b7 and the first sentence of subsection 7c77#a7 of such section shall apply to civil monetary penalties under this subsection in the same manner as such provisions apply to a penalty or proceeding under section #aabh;,a of the ,social ,security ,act4 7#e7 ,waivers ,the ,secretary may waive penalties under paragraph 7#b71 or extend the period of time for compliance with a requirement of this section1 for an entity in violation of this section that has made a good-faith effort to comply with this section4 7d7 ,rule of construction ,nothing in this section shall be construed to permit a health insurance issuer1 group health plan1 or other entity to restrict disclosure to1 or otherwise limit the access of1 the ,department of ,health and ,human ,services to a report described in subsection 7b77#a7 or information related to compliance with subsection 7a7 by such issuer1 plan1 or entity4 7e7 ,definition ,in this section1 the term wholesale acquisition cost has the meaning given such term in section #ahdg;,a7c77#f77;,b7 of the ,social ,security ,act4 2 and 7#b7 in section #bgbc 7#db ,u4,s4,c4 #cjj;gg-#bb7-- 7,a7 in subsection 7a7-- 7i7 in paragraph 7#a71 by inserting 7other than subsections 7a7 and 7b7 of section #bgii;,a-#aa7 after part ,d2 and 7ii7 in paragraph 7#b71 by inserting 7other than subsections 7a7 and 7b7 of section #bgii;,a-#aa7 after part ,d2 and 7,b7 in subsection 7b7-- 7i7 in paragraph 7#a71 by inserting 7other than subsections 7a7 and 7b7 of section #bgii;,a-#aa7 after part ,d2 7ii7 in paragraph 7#b77;,a71 by inserting 7other than subsections 7a7 and 7b7 of section #bgii;,a-#aa7 after part ,d2 and 7iii7 in paragraph 7#b77;,c77ii71 by inserting 7other than subsections 7a7 and 7b7 of section #bgii;,a-#aa7 after part ,d4 7b7 ,,erisa 7#a7 ,in general ,subtitle ,b of title ,i of the ,employee ,retirement ,income ,security ,act of #aigd 7#bi ,u4,s4,c4 #ajba et seq47 is amended-- 7,a7 in subpart ,b of part #g 7#bi ,u4,s4,c4 #aahe et seq471 by adding at the end the following3 #gbf4 ,oversight of pharmacy benefits manager services 7a7 ,in general ,for plan years beginning on or after ,january #a1 #bjbe1 a group health plan 7or health insurance issuer offering group health insurance coverage in connection with such a plan7 or an entity or subsidiary providing pharmacy benefits management services on behalf of such a plan or issuer shall not enter into a contract with a drug manufacturer1 distributor1 wholesaler1 subcontractor1 rebate aggregator1 or any associated third party that limits the disclosure of information to plan sponsors in such a manner that prevents the plan or issuer1 or an entity or subsidiary providing pharmacy benefits management services on behalf of a plan or issuer1 from making the reports described in subsection 7b74 7b7 ,reports 7#a7 ,in general ,for plan years beginning on or after ,january #a1 #bjbe1 not less frequently than annually1 a health insurance issuer offering group health insurance coverage or an entity providing pharmacy benefits management services on behalf of a group health plan or an issuer providing group health insurance coverage shall submit to the plan sponsor 7as defined in section #c7af77;,b77 of such group health plan or group health insurance coverage a report in accordance with this subsection and make such report available to the plan sponsor in a machine-readable format4 ,each such report shall include1 with respect to the applicable group health plan or health insurance coverage-- 7,a7 as applicable1 information collected from drug manufacturers by such issuer or entity on the total amount of copayment assistance dollars paid1 or copayment cards applied1 that were funded by the drug manufacturer with respect to the participants and beneficiaries in such plan or coverage2 7,b7 a list of each drug covered by such plan1 issuer1 or entity providing pharmacy benefits management services that was dispensed during the reporting period1 including1 with respect to each such drug during the reporting period-- 7i7 the brand name1 chemical entity1 and ,national ,drug ,code2 7ii7 the number of participants and beneficiaries for whom the drug was filled during the plan year1 the total number of prescription fills for the drug 7including original prescriptions and refills71 and the total number of dosage units of the drug dispensed across the plan year1 including whether the dispensing channel was by retail1 mail order1 or specialty pharmacy2 7iii7 the wholesale acquisition cost1 listed as cost per days supply and cost per pill1 or in the case of a drug in another form1 per dose2 7iv7 the total out-of-pocket spending by participants and beneficiaries on such drug1 including participant and beneficiary spending through copayments1 coinsurance1 and deductibles2 and 7v7 for any drug for which gross spending of the group health plan or health insurance coverage exceeded #aj1jjj during the reporting period-- 7,i7 a list of all other drugs in the same therapeutic category or class1 including brand name drugs and biological products and generic drugs or biosimilar biological products that are in the same therapeutic category or class as such drug2 and 7,,ii7 the rationale for preferred formulary placement of such drug in that therapeutic category or class1 if applicable2 7,c7 a list of each therapeutic category or class of drugs that were dispensed under the health plan or health insurance coverage during the reporting period1 and1 with respect to each such therapeutic category or class of drugs1 during the reporting period-- 7i7 total gross spending by the plan1 before manufacturer rebates1 fees1 or other manufacturer remuneration2 7ii7 the number of participants and beneficiaries who filled a prescription for a drug in that category or class2 7iii7 if applicable to that category or class1 a description of the formulary tiers and utilization mechanisms 7such as prior authorization or step therapy7 employed for drugs in that category or class2 7iv7 the total out-of-pocket spending by participants and beneficiaries1 including participant and beneficiary spending through copayments1 coinsurance1 and deductibles2 and 7v7 for each therapeutic category or class under which #c or more drugs are included on the formulary of such plan or coverage-- 7,i7 the amount received1 or expected to be received1 from drug manufacturers in rebates1 fees1 alternative discounts1 or other remuneration-- 7aa7 that has been paid1 or is to be paid1 by drug manufacturers for claims incurred during the reporting period2 or 7bb7 that is related to utilization of drugs1 in such therapeutic category or class2 7,,ii7 the total net spending1 after deducting rebates1 price concessions1 alternative discounts or other remuneration from drug manufacturers1 by the health plan or health insurance coverage on that category or class of drugs2 and 7,,iii7 the net price per course of treatment or single fill1 such as a #cj-;day supply or #ij-;day supply1 incurred by the health plan or health insurance coverage and its participants and beneficiaries1 after manufacturer rebates1 fees1 and other remuneration for drugs dispensed within such therapeutic category or class during the reporting period2 7,d7 total gross spending on prescription drugs by the plan or coverage during the reporting period1 before rebates and other manufacturer fees or remuneration2 7,e7 total amount received1 or expected to be received1 by the health plan or health insurance coverage in drug manufacturer rebates1 fees1 alternative discounts1 and all other remuneration received from the manufacturer or any third party1 other than the plan sponsor1 related to utilization of drug or drug spending under that health plan or health insurance coverage during the reporting period2 7,f7 the total net spending on prescription drugs by the health plan or health insurance coverage during the reporting period2 and 7,g7 amounts paid directly or indirectly in rebates1 fees1 or any other type of remuneration to brokers1 consultants1 advisors1 or any other individual or firm who referred the group health plan's or health insurance issuer's business to the pharmacy benefits manager4 7#b7 ,privacy requirements ,health insurance issuers offering group health insurance coverage and entities providing pharmacy benefits management services on behalf of a group health plan shall provide information under paragraph 7#a7 in a manner consistent with the privacy1 security1 and breach notification regulations promulgated under section #bfd7;c7 of the ,health ,insurance ,portability and ,accountability ,act of #aiif1 and shall restrict the use and disclosure of such information according to such privacy regulations4 7#c7 ,disclosure and redisclosure 7,a7 ,limitation to business associates ,a group health plan receiving a report under paragraph 7#a7 may disclose such information only to business associates of such plan as defined in section #afj4ajc of title #de1 ,code of ,federal ,regulations 7or successor regulations74 7,b7 ,clarification regarding public disclosure of information ,nothing in this section prevents a health insurance issuer offering group health insurance coverage or an entity providing pharmacy benefits management services on behalf of a group health plan from placing reasonable restrictions on the public disclosure of the information contained in a report described in paragraph 7#a71 except that such issuer or entity may not restrict disclosure of such report to the ,department of ,health and ,human ,services1 the ,department of ,labor1 the ,department of the ,treasury1 the ,comptroller ,general of the ,united ,states1 or applicable ,state agencies4 7,c7 ,limited form of report ,the ,secretary shall define through rulemaking a limited form of the report under paragraph 7#a7 required of plan sponsors who are drug manufacturers1 drug wholesalers1 or other direct participants in the drug supply chain1 in order to prevent anti-competitive behavior4 7#d7 ,report to ,,gao ,a health insurance issuer offering group health insurance coverage or an entity providing pharmacy benefits management services on behalf of a group health plan shall submit to the ,comptroller ,general of the ,united ,states each of the first #d reports submitted to a plan sponsor under paragraph 7#a7 with respect to such coverage or plan1 and other such reports as requested1 in accordance with the privacy requirements under paragraph 7#b71 the disclosure and redisclosure standards under paragraph 7#c71 the standards specified pursuant to paragraph 7#e71 and such other information that the ,comptroller ,general determines necessary to carry out the study under section #b7;d7 of the ,pharmacy ,benefits ,manager ,accountability ,act4 7#e7 ,standard format ,not later than ,june #a1 #bjbc1 the ,secretary shall specify through rulemaking standards for health insurance issuers and entities required to submit reports under paragraph 7#d7 to submit such reports in a standard format4 7c7 ,rule of construction ,nothing in this section shall be construed to permit a health insurance issuer1 group health plan1 or other entity to restrict disclosure to1 or otherwise limit the access of1 the ,department of ,labor to a report described in subsection 7b77#a7 or information related to compliance with subsection 7a7 by such issuer1 plan1 or entity4 7d7 ,definition ,in this section1 the term wholesale acquisition cost has the meaning given such term in section #ahdg;,a7c77#f77;,b7 of the ,social ,security ,act4 2 and 7,b7 in section #ejb 7#bi ,u4,s4,c4 #aacb7-- 7i7 in subsection 7a7-- 7,i7 in paragraph 7#f71 by striking or 7#i7 and inserting 7#i71 or 7#ac72 7,,ii7 in paragraph 7#aj71 by striking at the end or2 7,,iii7 in paragraph 7#aa71 at the end by striking the period and inserting 2 or2 and 7,,iv7 by adding at the end the following new paragraph3 7#ab7 by the ,secretary1 in consultation with the ,secretary of ,health and ,human ,services1 and the ,secretary of the ,treasury1 to enforce section #gbf4 2 7ii7 in subsection 7b77#c71 by inserting and subsections 7a77#ab7 and 7c77#ac7 before 1 the ,secretary is not2 and 7iii7 in subsection 7c71 by adding at the end the following new paragraph3 7#ac7 ,secretarial enforcement authority relating to oversight of pharmacy benefits manager services 7,a7 ,failure to provide timely information ,the ,secretary1 in consultation with the ,secretary of ,health and ,human ,services and the ,secretary of the ,treasury1 may impose a penalty against any health insurance issuer or entity providing pharmacy benefits management services that violates section #gbf7;a7 or fails to provide information required under section #gbf7;b7 in the amount of #aj1jjj for each day during which such violation continues or such information is not disclosed or reported4 7,b7 ,false information ,the ,secretary1 in consultation with the ,secretary of ,health and ,human ,services and the ,secretary of the ,treasury1 may impose a penalty against a health insurance issuer or entity providing pharmacy benefits management services that knowingly provides false information under section #gbf in an amount not to exceed #ajj1jjj for each item of false information4 ,such penalty shall be in addition to other penalties as may be prescribed by law4 7,c7 ,waivers ,the ,secretary may waive penalties under subparagraph 7,a71 or extend the period of time for compliance with a requirement of section #gbf1 for an entity in violation of such section that has made a good-faith effort to comply with such section4 4 7#b7 ,clerical amendment ,the table of contents in section #a of the ,employee ,retirement ,income ,security ,act of #aigd 7#bi ,u4,s4,c4 #ajja et seq47 is amended by inserting after the item relating to section #gbe the following new item3 ,sec4 #gbf4 ,oversight of pharmacy benefits manager services4 4 7c7 ,,irc 7#a7 ,in general ,subchapter ,b of chapter #ajj of the ,internal ,revenue ,code of #aihf is amended by adding at the end the following3 #ihbf4 ,oversight of pharmacy benefits manager services 7a7 ,in general ,for plan years beginning on or after ,january #a1 #bjbe1 a group health plan or an entity or subsidiary providing pharmacy benefits management services on behalf of such a plan shall not enter into a contract with a drug manufacturer1 distributor1 wholesaler1 subcontractor1 rebate aggregator1 or any associated third party that limits the disclosure of information to plan sponsors in such a manner that prevents the plan1 or an entity or subsidiary providing pharmacy benefits management services on behalf of a plan1 from making the reports described in subsection 7b74 7b7 ,reports 7#a7 ,in general ,for plan years beginning on or after ,january #a1 #bjbe1 not less frequently than annually1 an entity providing pharmacy benefits management services on behalf of a group health plan shall submit to the plan sponsor 7as defined in section #c7af77;,b7 of the ,employee ,retirement ,income ,security ,act of #aigd7 of such group health plan a report in accordance with this subsection and make such report available to the plan sponsor in a machine-readable format4 ,each such report shall include1 with respect to the applicable group health plan-- 7,a7 as applicable1 information collected from drug manufacturers by such entity on the total amount of copayment assistance dollars paid1 or copayment cards applied1 that were funded by the drug manufacturer with respect to the participants and beneficiaries in such plan2 7,b7 a list of each drug covered by such plan or entity providing pharmacy benefits management services that was dispensed during the reporting period1 including1 with respect to each such drug during the reporting period-- 7i7 the brand name1 chemical entity1 and ,national ,drug ,code2 7ii7 the number of participants and beneficiaries for whom the drug was filled during the plan year1 the total number of prescription fills for the drug 7including original prescriptions and refills71 and the total number of dosage units of the drug dispensed across the plan year1 including whether the dispensing channel was by retail1 mail order1 or specialty pharmacy2 7iii7 the wholesale acquisition cost1 listed as cost per days supply and cost per pill1 or in the case of a drug in another form1 per dose2 7iv7 the total out-of-pocket spending by participants and beneficiaries on such drug1 including participant and beneficiary spending through copayments1 coinsurance1 and deductibles2 and 7v7 for any drug for which gross spending of the group health plan exceeded #aj1jjj during the reporting period-- 7,i7 a list of all other drugs in the same therapeutic category or class1 including brand name drugs and biological products and generic drugs or biosimilar biological products that are in the same therapeutic category or class as such drug2 and 7,,ii7 the rationale for preferred formulary placement of such drug in that therapeutic category or class1 if applicable2 7,c7 a list of each therapeutic category or class of drugs that were dispensed under the health plan during the reporting period1 and1 with respect to each such therapeutic category or class of drugs1 during the reporting period-- 7i7 total gross spending by the plan1 before manufacturer rebates1 fees1 or other manufacturer remuneration2 7ii7 the number of participants and beneficiaries who filled a prescription for a drug in that category or class2 7iii7 if applicable to that category or class1 a description of the formulary tiers and utilization mechanisms 7such as prior authorization or step therapy7 employed for drugs in that category or class2 7iv7 the total out-of-pocket spending by participants and beneficiaries1 including participant and beneficiary spending through copayments1 coinsurance1 and deductibles2 and 7v7 for each therapeutic category or class under which #c or more drugs are included on the formulary of such plan-- 7,i7 the amount received1 or expected to be received1 from drug manufacturers in rebates1 fees1 alternative discounts1 or other remuneration-- 7aa7 that has been paid1 or is to be paid1 by drug manufacturers for claims incurred during the reporting period2 or 7bb7 that is related to utilization of drugs1 in such therapeutic category or class2 7,,ii7 the total net spending1 after deducting rebates1 price concessions1 alternative discounts or other remuneration from drug manufacturers1 by the health plan on that category or class of drugs2 and 7,,iii7 the net price per course of treatment or single fill1 such as a #cj-;day supply or #ij-;day supply1 incurred by the health plan and its participants and beneficiaries1 after manufacturer rebates1 fees1 and other remuneration for drugs dispensed within such therapeutic category or class during the reporting period2 7,d7 total gross spending on prescription drugs by the plan during the reporting period1 before rebates and other manufacturer fees or remuneration2 7,e7 total amount received1 or expected to be received1 by the health plan in drug manufacturer rebates1 fees1 alternative discounts1 and all other remuneration received from the manufacturer or any third party1 other than the plan sponsor1 related to utilization of drug or drug spending under that health plan during the reporting period2 7,f7 the total net spending on prescription drugs by the health plan during the reporting period2 and 7,g7 amounts paid directly or indirectly in rebates1 fees1 or any other type of remuneration to brokers1 consultants1 advisors1 or any other individual or firm who referred the group health plan's business to the pharmacy benefits manager4 7#b7 ,privacy requirements ,entities providing pharmacy benefits management services on behalf of a group health plan shall provide information under paragraph 7#a7 in a manner consistent with the privacy1 security1 and breach notification regulations promulgated under section #bfd7;c7 of the ,health ,insurance ,portability and ,accountability ,act of #aiif1 and shall restrict the use and disclosure of such information according to such privacy regulations4 7#c7 ,disclosure and redisclosure 7,a7 ,limitation to business associates ,a group health plan receiving a report under paragraph 7#a7 may disclose such information only to business associates of such plan as defined in section #afj4ajc of title #de1 ,code of ,federal ,regulations 7or successor regulations74 7,b7 ,clarification regarding public disclosure of information ,nothing in this section prevents an entity providing pharmacy benefits management services on behalf of a group health plan from placing reasonable restrictions on the public disclosure of the information contained in a report described in paragraph 7#a71 except that such entity may not restrict disclosure of such report to the ,department of ,health and ,human ,services1 the ,department of ,labor1 the ,department of the ,treasury1 the ,comptroller ,general of the ,united ,states1 or applicable ,state agencies4 7,c7 ,limited form of report ,the ,secretary shall define through rulemaking a limited form of the report under paragraph 7#a7 required of plan sponsors who are drug manufacturers1 drug wholesalers1 or other direct participants in the drug supply chain1 in order to prevent anti-competitive behavior4 7#d7 ,report to ,,gao ,an entity providing pharmacy benefits management services on behalf of a group health plan shall submit to the ,comptroller ,general of the ,united ,states each of the first #d reports submitted to a plan sponsor under paragraph 7#a7 with respect to such plan1 and other such reports as requested1 in accordance with the privacy requirements under paragraph 7#b71 the disclosure and redisclosure standards under paragraph 7#c71 the standards specified pursuant to paragraph 7#e71 and such other information that the ,comptroller ,general determines necessary to carry out the study under section #b7;d7 of the ,pharmacy ,benefits ,manager ,accountability ,act4 7#e7 ,standard format ,not later than ,june #a1 #bjbc1 the ,secretary shall specify through rulemaking standards for entities required to submit reports under paragraph 7#d7 to submit such reports in a standard format4 7c7 ,enforcement 7#a7 ,in general ,the ,secretary1 in consultation with the ,secretary of ,labor and the ,secretary of ,health and ,human ,services1 shall enforce this section4 7#b7 ,failure to provide timely information ,an entity providing pharmacy benefits management services that violates subsection 7a7 or fails to provide information required under subsection 7b7 shall be subject to a civil monetary penalty in the amount of #aj1jjj for each day during which such violation continues or such information is not disclosed or reported4 7#c7 ,false information ,an entity providing pharmacy benefits management services that knowingly provides false information under this section shall be subject to a civil money penalty in an amount not to exceed #ajj1jjj for each item of false information4 ,such civil money penalty shall be in addition to other penalties as may be prescribed by law4 7#d7 ,procedure ,the provisions of section #aabh;,a of the ,social ,security ,act1 other than subsection 7a7 and 7b7 and the first sentence of subsection 7c77#a7 of such section shall apply to civil monetary penalties under this subsection in the same manner as such provisions apply to a penalty or proceeding under section #aabh;,a of the ,social ,security ,act4 7#e7 ,waivers ,the ,secretary may waive penalties under paragraph 7#b71 or extend the period of time for compliance with a requirement of this section1 for an entity in violation of this section that has made a good-faith effort to comply with this section4 7d7 ,rule of construction ,nothing in this section shall be construed to permit a group health plan or other entity to restrict disclosure to1 or otherwise limit the access of1 the ,department of the ,treasury to a report described in subsection 7b77#a7 or information related to compliance with subsection 7a7 by such plan or entity4 7e7 ,definition ,in this section1 the term wholesale acquisition cost has the meaning given such term in section #ahdg;,a7c77#f77;,b7 of the ,social ,security ,act4 4 7#b7 ,clerical amendment ,the table of sections for subchapter ,b of chapter #ajj of the ,internal ,revenue ,code of #aihf is amended by adding at the end the following new item3 ,sec4 #ihbf4 ,oversight of pharmacy benefits manager services4 4 7d7 ,,gao study 7#a7 ,in general ,not later than #c years after the date of enactment of this ,act1 the ,comptroller ,general of the ,united ,states shall submit to ,congress a report on-- 7,a7 pharmacy networks of group health plans1 health insurance issuers1 and entities providing pharmacy benefits management services under such group health plan or group or individual health insurance coverage1 including networks that have pharmacies that are under common ownership 7in whole or part7 with group health plans1 health insurance issuers1 or entities providing pharmacy benefits management services or pharmacy benefits administrative services under group health plan or group or individual health insurance coverage2 7,b7 as it relates to pharmacy networks that include pharmacies under common ownership described in subparagraph 7,a7-- 7i7 whether such networks are designed to encourage enrollees of a plan or coverage to use such pharmacies over other network pharmacies for specific services or drugs1 and if so1 the reasons the networks give for encouraging use of such pharmacies2 and 7ii7 whether such pharmacies are used by enrollees disproportionately more in the aggregate or for specific services or drugs compared to other network pharmacies2 7,c7 whether group health plans and health insurance issuers offering group or individual health insurance coverage have options to elect different network pricing arrangements in the marketplace with entities that provide pharmacy benefits management services1 the prevalence of electing such different network pricing arrangements2 7,d7 pharmacy network design parameters that encourage enrollees in the plan or coverage to fill prescriptions at mail order1 specialty1 or retail pharmacies that are wholly or partially-owned by that issuer or entity2 and 7,e7 the degree to which mail order1 specialty1 or retail pharmacies that dispense prescription drugs to an enrollee in a group health plan or health insurance coverage that are under common ownership 7in whole or part7 with group health plans1 health insurance issuers1 or entities providing pharmacy benefits management services or pharmacy benefits administrative services under group health plan or group or individual health insurance coverage receive reimbursement that is greater than the median price charged to the group health plan or health insurance issuer when the same drug is dispensed to enrollees in the plan or coverage by other pharmacies included in the pharmacy network of that plan1 issuer1 or entity that are not wholly or partially owned by the health insurance issuer or entity providing pharmacy benefits management services4 7#b7 ,requirement ,the ,comptroller ,general of the ,united ,states shall ensure that the report under paragraph 7#a7 does not contain information that would allow a reader to identify a specific plan or entity providing pharmacy benefits management services or otherwise contain commercial or financial information that is privileged or confidential4 7#c7 ,definitions ,in this subsection1 the terms group health plan1 health insurance coverage1 and health insurance issuer have the meanings given such terms in section #bgia of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #cjj;gg-#ia74 ,,ii ,supporting patients1 health care workers1 community health centers1 and hospitals #bja4 ,extension for community health centers1 the national health service corps1 and teaching health centers that operate ,,gme programs 7a7 ,teaching health centers that operate graduate medical education programs ,section #cdj;,h7g7 of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bef;h7g77 is amended-- 7#a7 by amending paragraph 7#a7 to read as follows3 7#a7 ,in general ,to carry out this section1 there are appropriated such sums as may be necessary1 not to exceed-- 7,a7 #bcj1jjj1jjj1 for the period of fiscal years #bjaa through #bjae2 7,b7 #fj1jjj1jjj for each of fiscal years #bjaf and #bjag2 7,c7 #abf1ejj1jjj for each of fiscal years #bjah through #bjbc2 7,d7 #age1jjj1jjj for each of fiscal years #bjbd and #bjbe2 7,e7 #bbe1jjj1jjj for each of fiscal years #bjbf and #bjbg2 and 7,f7 #bge1jjj1jjj for each of fiscal years #bjbh and #bjbi4 2 and 7#b7 by adding at the end the following3 7#c7 ,availability ,the amounts made available under paragraph 7#a7 shall remain available until expended4 4 7b7 ,extension for community health centers ,section #ajejc7;b77#a77;,f7 of the ,patient ,protection and ,affordable ,care ,act 7#db ,u4,s4,c4 #bed;b-#b7;b77#a77;,f77 is amended-- 7#a7 by striking and before #d1jjj1jjj1jjj and inserting a comma2 and 7#b7 by inserting 1 and #d1bjj1jjj1jjj for each of fiscal years #bjbd and #bjbe before the semicolon4 7c7 ,extension for the ,national ,health ,service ,corps ,section #ajejc7;b77#b7 of the ,patient ,protection and ,affordable ,care ,act 7#db ,u4,s4,c4 #bed;b-#b7;b77#b77 is amended-- 7#a7 in subparagraph 7,g71 by striking and at the end2 7#b7 in subparagraph 7,h71 by striking the period at the end and inserting 2 and2 and 7#c7 by adding at the end the following3 7,i7 #cej1jjj1jjj for each of fiscal years #bjbd and #bjbe4 4 7d7 ,application of provisions ,amounts appropriated pursuant to the amendments made by this section shall be subject to the requirements contained in ,public ,law #aag-cbh for funds for programs authorized under sections #ccj through #cdj of the ,public ,health ,service ,act4 7e7 ,conforming amendment ,paragraph 7#d7 of section #cjad7;h7 of title #ah1 ,united ,states ,code1 is amended by striking and section #cja7;d7 of division ,,bb of the ,consolidated ,appropriations ,act1 #bjba4 and inserting section #cja7;d7 of division ,,bb of the ,consolidated ,appropriations ,act1 #bjba1 and section #bja7;d7 of the ,,patient ,act of #bjbc4 #bjb4 ,extension of special diabetes programs 7a7 ,extension of special diabetes programs for type i diabetes ,section #ccj;,b7b77#b7 of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bed;c-#b7;b77#b77 is amended-- 7#a7 in subparagraph 7,c71 by striking and at the end2 7#b7 in subparagraph 7,d71 by striking the period and inserting 2 and2 and 7#c7 by adding at the end the following new subparagraph3 7,e7 #agj1jjj1jjj for each of fiscal years #bjbd and #bjbe4 4 7b7 ,extending funding for special diabetes programs for indians ,section #ccj;,c7c77#b7 of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bed;c-#c7;c77#b77 is amended-- 7#a7 in subparagraph 7,c71 by striking and at the end2 7#b7 in subparagraph 7,d71 by striking the period and inserting 2 and2 and 7#c7 by adding at the end the following new subparagraph3 7,e7 #agj1jjj1jjj for each of fiscal years #bjbd and #bjbe4 4 #bjc4 ,delaying certain disproportionate share hospital payment reductions under the ,medicaid program ,section #aibc7;f77#g77;,a7 of the ,social ,security ,act 7#db ,u4,s4,c4#acifr-#d7;f77#g77;,a77 is amended-- 7#a7 in clause 7i71 in the matter preceding subclause 7,i71 by striking #bjbd and inserting #bjbf2 and 7#b7 in clause 7ii71 by striking #bjbd and inserting #bjbf4 #bjd4 ,medicaid improvement fund ,section #aida7;b77#c77;,a7 of the ,social ,security ,act 7#db ,u4,s4,c4 #acifw-#a7;b77#c77;,a77 is amended by striking #g1jjj1jjj1jjj and inserting #j4 ,,iii ,reducing health care costs #cja4 ,increasing transparency in generic drug applications 7a7 ,in general ,section #eje7;j77#c7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cee7;j77#c77 is amended by adding at the end the following3 7,h7 7i7 ,upon request 7in controlled correspondence or an analogous process7 by a person that has submitted or intends to submit an abbreviated application under this subsection for a drug that is required by regulation to contain one or more of the same inactive ingredients in the same concentrations as the listed drug referred to1 or for which the ,secretary determines there is a scientific justification for an approach that is in vitro in whole or in part to be used to demonstrate bioequivalence for a drug if such a drug contains one or more of the same inactive ingredients in the same concentrations as the listed drug1 the ,secretary shall inform the person whether such drug is qualitatively and quantitatively the same as the listed drug4 ,the ,secretary may also provide such information to such a person on the ,secretary's own initiative during the review of an abbreviated application under this subsection for such drug4 7ii7 ,notwithstanding section #cja7;j71 if the ,secretary determines that such drug is not qualitatively or quantitatively the same as the listed drug1 the ,secretary shall identify and disclose to the person-- 7,i7 the ingredient or ingredients that cause such drug not to be qualitatively or quantitatively the same as the listed drug2 and 7,,ii7 for any ingredient for which there is an identified quantitative deviation1 whether the quantity or proportion of any ingredient in such drug is greater than or less than the quantity or proportion of such ingredient in the listed drug4 7iii7 ,if the ,secretary determines that such drug is qualitatively and quantitatively the same as the listed drug1 the ,secretary shall not change or rescind such determination after the submission of an abbreviated application for such drug under this subsection unless-- 7,i7 the formulation of the listed drug has been changed and the ,secretary has determined that the prior listed drug formulation was withdrawn for reasons of safety or effectiveness2 or 7,,ii7 the ,secretary makes a written determination that the prior determination must be changed because an error has been identified4 7iv7 ,if the ,secretary makes a written determination described in clause 7iii77,,ii71 the ,secretary shall provide notice and a copy of the written determination to the person making the request under clause 7i74 7v7 ,the disclosures required by this subparagraph are disclosures authorized by law1 including for purposes of section #aije of title #ah1 ,united ,states ,code4 4 7b7 ,guidance 7#a7 ,in general ,not later than one year after the date of enactment of this ,act1 the ,secretary of ,health and ,human ,services shall issue draft guidance1 or update guidance1 describing how the ,secretary will determine whether a drug is qualitatively and quantitatively the same as the listed drug 7as such terms are used in section #eje7;j77#c77;,h7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act1 as added by subsection 7a771 including with respect to assessing p,h adjusters4 7#b7 ,process ,in issuing guidance under this subsection1 the ,secretary of ,health and ,human ,services shall-- 7,a7 publish draft guidance2 7,b7 provide a period of at least #fj days for comment on the draft guidance2 and 7,c7 after considering any comments received and not later than one year after the close of the comment period on the draft guidance1 publish final guidance4 7c7 ,applicability ,section #eje7;j77#c77;,h7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act1 as added by subsection 7a71 applies beginning on the date of enactment of this ,act1 irrespective of the date on which the guidance required by subsection 7b7 is finalized4 #cjb4 ,parity in ,medicare payments for hospital outpatient department services furnished off-campus 7a7 ,in general ,section #ahcc7t77#af7 of the ,social ,security ,act 7#db ,u4,s4,c4 #aciel7t77#af77 is amended by adding at the end the following new subparagraph3 7,h7 ,parity in fee schedule amount for certain services furnished by an off-campus outpatient department of a provider 7i7 ,in general ,subject to clause 7iii71 in the case of specified ,,opd services 7as defined in clause 7iv77 that are furnished during #bjbe or a subsequent year by an off-campus outpatient department of a provider 7as defined in clause 7iv771 there shall be substituted for the amount otherwise determined under this subsection for such service and year an amount equal to the payment amount that would have been payable under the applicable payment system under this part 7other than under this subsection7 had such services been furnished by such a department subject to such payment system pursuant to paragraph 7#ba77;,c74 7ii7 ,not budget neutral implementation ,in making any budget neutrality adjustments under this subsection for #bjbe or a subsequent year1 the ,secretary shall not take into account the reduced expenditures that result from the application of this subparagraph4 7iii7 ,transition ,the ,secretary shall provide for a #d-year phase-in of the application of clause 7i71 with clause 7i7 being fully applicable for specified ,,opd services beginning with #bjbh4 7iv7 ,definitions ,for purposes of this subparagraph3 7,i7 ,designated ambulatory payment classification group ,the term designated ambulatory payment classification group means an ambulatory payment classification group for drug administration services4 7,,ii7 ,specified ,,opd services defined ,the term specified ,,opd services means covered ,,opd services included in a designated ambulatory payment classification group4 7,,iii7 ,off-campus outpatient department of a provider defined ,the term off-campus outpatient department of a provider means a department of a provider 7as defined in section #dac4fe7;a77#b7 of title #db1 ,code of ,federal ,regulations7 that is not located-- 7aa7 on the campus 7as such term is defined in such section #dac4fe7;a77#b77 of such provider2 or 7bb7 within the distance 7described in such definition of campus7 from a remote location of a hospital facility 7as defined in such section #dac4fe7;a77#b774 4 7b7 ,implementation ,section #ahcc7t77#ab7 of the ,social ,security ,act 7#db ,u4,s4,c4 #aciel7t77#ab77 is amended-- 7#a7 in subparagraph 7,d71 by striking and at the end2 7#b7 in subparagraph 7,e71 by striking the period at the end and inserting 2 and2 and 7#c7 by adding at the end the following new subparagraph3 7,f7 the determination of any payment amount under paragraph 7#af77;,h71 including the transition under clause 7iii7 of such paragraph4 4 #cjc4 ,improving transparency and preventing the use of abusive spread pricing and related practices in ,medicaid 7a7 ,pharmacy price reimbursement requirements 7#a7 ,in general ,section #aibg7;e7 of the ,social ,security ,act 7#db ,u4,s4,c4 #acifr-#h7;e77 is amended by adding at the end the following3 7#f7 ,pharmacy price reimbursement required ,a contract between the ,state and a managed care entity 7or subcontractor of a managed care entity that manages the pharmacy benefit for such entity 7in this section referred to as a ,,pbm71 or other specified entity 7as such terms are defined in section #aijc7m77#i77;,d77 that includes provisions making the managed care entity responsible for coverage of covered outpatient drugs dispensed to individuals enrolled with the entity1 shall require that payment for such drugs and related administrative services 7as applicable71 including payments made by a ,,pbm on behalf of the ,state or entity1 is based on a pass-through pricing model under which-- 7,a7 any payment made by the entity or the ,,pbm 7as applicable7 for such a drug-- 7i7 is limited to-- 7,i7 ingredient cost2 and 7,,ii7 a professional dispensing fee that is not less than the professional dispensing fee that the ,state plan or waiver would pay if the plan or waiver was making the payment directly2 7ii7 is passed through in its entirety by the entity or ,,pbm to the pharmacy or provider that dispenses the drug2 and 7iii7 is made in a manner that is consistent with sections #ddg4ejb1 #ddg4eab1 #ddg4ead1 and #ddg4eah of title #db1 ,code of ,federal ,regulations 7or any successor regulation7 as if such requirements applied directly to the entity or the ,,pbm2 7,b7 payment to the entity or the ,,pbm 7as applicable7 for administrative services performed by the entity or ,,pbm is limited to an administrative fee that covers the reasonable cost of providing such services2 7,c7 the entity or the ,,pbm 7as applicable7 shall make available to the ,state1 and the ,secretary upon request1 all costs and payments related to covered outpatient drugs and accompanying administrative services incurred1 received1 or made by the entity or the ,,pbm1 including ingredient costs1 professional dispensing fees1 administrative fees1 post-sale and post-invoice fees1 discounts1 or related adjustments such as direct and indirect remuneration fees1 and any and all other remuneration2 and 7,d7 any form of spread pricing whereby any amount charged or claimed by the entity or the ,,pbm 7as applicable7 is in excess of the amount paid to the pharmacies on behalf of the entity1 including any post-sale or post-invoice fees1 discounts1 or related adjustments such as direct and indirect remuneration fees or assessments 7after allowing for a reasonable administrative fee as described in subparagraph 7,b77 is not allowable for purposes of claiming ,federal matching payments under this title4 4 7#b7 ,conforming amendments ,section #aijc7m77#b77;,a77xiii7 of such ,act 7#db ,u4,s4,c4 #acif;b7m77#b77;,a77xiii77 is amended-- 7,a7 by striking and 7,,iii7 and inserting 7,,iii72 7,b7 by inserting before the period at the end the following3 1 and 7,,iv7 the pharmacy benefit provided by the entity 7or pharmacy benefit manager on behalf of the entity under a contract71 the other specified entity 7as defined in paragraph 7#i77;,d771 or by another arrangement between the entity and the pharmacy benefit manager1 shall comply with the requirements of section #aibg7;e77#f72 and 7,c7 by moving the left margin #b ems to the left4 7#c7 ,effective date ,the amendments made by this subsection apply to contracts between ,states and managed care entities1 or other specified entities1 that have an initial effective date or are renewed on or after the date that is #ah months after the date of enactment of this ,act4 7b7 ,ensuring accurate payments to pharmacies under ,medicaid 7#a7 ,in general ,section #aibg7;f7 of the ,social ,security ,act 7#db ,u4,s4,c4 #acifr-#h7;f77 is amended-- 7,a7 by striking and after the semicolon at the end of paragraph 7#a77;,a77i7 and all that precedes it through 7#a7 and inserting the following3 7#a7 ,determining pharmacy actual acquisition costs ,the ,secretary shall conduct a survey of retail community pharmacy drug prices to determine the national average drug acquisition cost as follows3 7,a7 ,use of vendor ,the ,secretary may contract services for-- 7i7 with respect to retail community pharmacies1 the determination of retail survey prices of the national average drug acquisition cost for covered outpatient drugs based on a monthly survey of such pharmacies2 and 2 7,b7 by adding at the end of paragraph 7#a7 the following3 7,f7 ,survey reporting ,a ,state shall require that any retail community pharmacy in the ,state that receives any payment1 reimbursement1 administrative fee1 discount1 or rebate related to the dispensing of covered outpatient drugs to individuals receiving benefits under this title1 regardless of whether such payment1 reimbursement1 administrative fee1 discount1 or rebate is received from the ,state or a managed care entity directly or from a pharmacy benefit manager or other specified entity 7as defined in section #aijc7m77#i77;,d77 that has a contract with the ,state or a managed care entity1 shall respond to surveys of retail prices conducted under this subsection4 7,g7 ,survey information ,information on national drug acquisition prices obtained under this paragraph shall be made publicly available in a timely manner following the collection of such information and shall include at least the following3 7i7 ,the monthly response rate to the survey including a list of pharmacies not in compliance with subparagraph 7,f74 7ii7 ,the sampling frame and number of pharmacies sampled monthly4 7iii7 ,information on price concessions to the pharmacy1 including discounts1 rebates1 and other price concessions1 to the extent that such information is available during the survey period4 7,h7 ,report on specialty pharmacies ,not later than #a year after the date that this subparagraph takes effect1 the ,secretary shall submit to ,congress a report examining specialty drug coverage and reimbursement under this title1 including-- 7i7 a description of how ,state ,medicaid programs define specialty drugs and specialty pharmacies2 7ii7 the amount ,state ,medicaid programs pay for specialty drugs2 7iii7 how ,states and managed care entities determine payment for specialty drugs2 7iv7 the settings in which specialty drugs are dispensed to individuals receiving benefits under this title 7such as retail community pharmacies or specialty pharmacies72 7v7 the extent to which speciality drugs 7as defined by the respective ,states7 are captured in the national average drug acquisition cost survey 7or through another process72 7vi7 examples of specialty drug dispensing fees to support the services associated with dispensing such specialty drugs2 and 7vii7 recommendations as to whether specialty pharmacies should be included in the survey of retail prices to ensure national average drug acquisition costs capture drugs sold at specialty pharmacies1 and how such specialty pharmacies should be defined4 7,i7 ,enforcement ,at the discretion of the ,secretary1 the ,secretary may enforce non-compliance with this paragraph by a pharmacy through the establishment of penalties or the suspension of payments under this title1 in full or in part1 until compliance with this paragraph has been completed4 2 and 7,c7 in paragraph 7#b7-- 7i7 in subparagraph 7,a71 by inserting 7including payment rates under ,medicaid managed care plans7 after under this title2 and 7ii7 in subparagraph 7,b71 by inserting 1 and the basis for such dispensing fees before the semicolon at the end4 7#b7 ,effective date ,the amendments made by this subsection take effect on the first day of the first quarter that begins on or after the date that is #ah months after the date of enactment of this ,act4